DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $224,323,764 | +1.9% | 904,175 | -1.4% | 0.40% | +4.9% |
| Q2 2023 | $220,065,840 | -18.6% | 916,941 | -14.5% | 0.38% | -23.5% |
| Q1 2023 | $270,315,464 | -3.9% | 1,072,513 | +1.2% | 0.50% | -19.7% |
| Q4 2022 | $281,402,041 | +17.9% | 1,060,205 | +14.7% | 0.62% | +17.5% |
| Q3 2022 | $238,651,000 | +5.9% | 923,978 | +4.2% | 0.53% | +9.2% |
| Q2 2022 | $225,404,000 | -8.7% | 886,690 | +5.3% | 0.49% | -1.8% |
| Q1 2022 | $246,831,000 | -32.0% | 841,697 | -23.7% | 0.50% | -27.2% |
| Q4 2021 | $362,890,000 | +12.7% | 1,102,420 | +4.3% | 0.68% | +0.7% |
| Q3 2021 | $322,044,000 | +17.6% | 1,056,991 | +3.6% | 0.68% | +11.4% |
| Q2 2021 | $273,880,000 | +21.6% | 1,019,908 | +1.9% | 0.61% | +6.9% |
| Q1 2021 | $225,282,000 | +5.0% | 1,001,196 | +3.7% | 0.57% | +2.3% |
| Q4 2020 | $214,569,000 | +0.2% | 965,844 | -2.8% | 0.56% | -10.5% |
| Q3 2020 | $214,124,000 | +43.6% | 994,112 | +17.9% | 0.62% | +33.9% |
| Q2 2020 | $149,098,000 | +43.5% | 843,370 | +12.3% | 0.46% | +21.2% |
| Q1 2020 | $103,925,000 | +54.0% | 750,800 | +70.7% | 0.38% | +90.0% |
| Q4 2019 | $67,504,000 | +30.9% | 439,878 | +23.1% | 0.20% | +52.3% |
| Q3 2019 | $51,564,000 | -5.5% | 357,401 | -6.3% | 0.13% | -25.8% |
| Q2 2019 | $54,568,000 | +4.1% | 381,619 | -3.9% | 0.18% | +1.1% |
| Q1 2019 | $52,442,000 | +61.3% | 397,158 | +31.6% | 0.18% | +51.7% |
| Q4 2018 | $32,521,000 | +2.0% | 301,805 | +2.9% | 0.12% | 0.0% |
| Q3 2018 | $31,880,000 | -15.0% | 293,387 | -22.8% | 0.12% | -9.4% |
| Q2 2018 | $37,516,000 | +16.7% | 380,165 | +15.8% | 0.13% | +4.1% |
| Q1 2018 | $32,147,000 | +16.0% | 328,337 | +10.0% | 0.12% | +28.1% |
| Q4 2017 | $27,708,000 | +14.3% | 298,516 | +5.6% | 0.10% | +11.6% |
| Q3 2017 | $24,249,000 | -22.6% | 282,687 | -23.8% | 0.09% | -31.2% |
| Q2 2017 | $31,317,000 | +1.4% | 371,106 | +2.8% | 0.12% | -7.4% |
| Q1 2017 | $30,876,000 | +15.6% | 360,986 | +5.2% | 0.14% | +4.7% |
| Q4 2016 | $26,698,000 | +2.7% | 342,991 | +3.4% | 0.13% | -2.3% |
| Q3 2016 | $25,991,000 | -20.9% | 331,558 | +1.9% | 0.13% | -33.0% |
| Q2 2016 | $32,877,000 | +10.2% | 325,506 | +3.5% | 0.20% | +5.9% |
| Q1 2016 | $29,827,000 | +32.6% | 314,425 | +29.8% | 0.19% | +35.8% |
| Q4 2015 | $22,495,000 | +44.4% | 242,192 | +32.5% | 0.14% | -4.2% |
| Q3 2015 | $15,577,000 | +19.1% | 182,803 | +19.6% | 0.14% | +21.2% |
| Q2 2015 | $13,079,000 | -4.0% | 152,808 | -4.7% | 0.12% | 0.0% |
| Q1 2015 | $13,621,000 | -5.0% | 160,415 | -4.1% | 0.12% | -7.1% |
| Q4 2014 | $14,336,000 | – | 167,314 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |